News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Campbell Alliance Announces Windhover Top 10 Oncology Projects for 2011



11/30/2011 10:03:14 AM

RALEIGH, N.C., Nov. 29, 2011 /PRNewswire/ -- Campbell Alliance, an inVentiv Health company and the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced the assets chosen for the 2011 Top 10 Most Licensable Oncology Projects to Watch. Selected projects will be discussed in more detail at the upcoming Windhover Therapeutic Area Partnerships conference (http://www.tapartnerships.com) in Boston, November 30 through December 2.

Narrowed from a field of over 1,700 oncology assets using a strict set of judging criteria, the selected projects represent what are considered the most attractive licensable oncology opportunities the industry has to offer. Specifically, the selection team focused on what are considered "hot areas" in oncology: those with transformational, nascent therapies where the potential for differentiation is high. Conjugated antibody, cancer metabolism, and immuno-oncology technologies dominated the list this year.

"Our approach this year was to look at differentiated molecular pathways and technologies," said Jonathon Fendelman, Senior Practice Executive at Campbell Alliance. "While these targeted approaches tend to address smaller patient populations initially, a great deal of potential exists for add-on indications, which makes them attractive licensing opportunities. Further, strong differentiation raises the likelihood of reimbursement post-approval, which is key in an increasingly payer-driven market."

2011 Top 10 Most Licensable Oncology Projects to Watch

Company

Asset/Compound

Location

Website

Advaxis

ADXS-HPV

US/New Jersey

www.advaxis.com

Altor

ALT-801

US/Florida

www.altorbioscience.com

Aveo

Ficlatuzumab

US/Massachusetts

www.aveopharma.com

Biotest AG

BT-062

Germany

www.biotest.com

Celldex

CDX-011

US/Massachusetts

www.celldextherapeutics.com

Endocyte

EC145

US/Indiana

www.endocyte.com

ImmunoCellular Therapeutics

ICT-107

US/California

www.imuc.com

Immune System Therapeutics

MDX 1097

Australia

www.istl.com.au

Neogenix Oncology

Ensituximab/NPC-1C

US/New York

www.neogenix.com

Ruga

STF-31

US/California

www.rugacorp.com


Campbell Alliance has served as advisor for the oncology track of the Therapeutic Area Partnerships event since 2007. More information on Campbell Alliance's Top 10 Oncology Projects can be found at http://www.campbellalliance.com/OncTop10.

Windhover originally announced the full list of companies selected as part of the Therapeutic Area Partnerships conference on November 1. The list included assets from each of several therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases, and inflammatory/autoimmune, plus a "hot space" category, including ophthalmology, orphan diseases, and women's health.

About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, New York City, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.


CONTACT:

James Forte

Director, Public and Media Relations

Campbell Alliance

919-844-7100, extension 7195

jforte@campbellalliance.com

SOURCE Campbell Alliance


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES